• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Report finds ethosomes as promising transdermal delivery mechanism

October 7, 2016 By Sarah Faulkner

Ethosomes as promising transdermal delivery mechanismEthosomes – nanocarriers loaded with ethanol – can penetrate the skin’s protective layers and deliver a variety of drugs, a review published in Current Clinical Pharmacology reported today.

Transdermal delivery of drugs is touted by some researchers as promising, since it’s noninvasive and avoids any interaction with the gastrointestinal tract. Ethosomes are malleable and their ethanol-filled core allows them to disrupt the skin’s protective lipid bilayer.

The review highlighted preclinical and clinical trials that demonstrate the nanovesicles’ efficacy, including delivering antimicrobials and anti-inflammatory drugs with enhanced penetration and diffusion. The review’s authors also point to drugs that act on the central nervous system – when delivered using an ethosome, the drugs exhibited enhanced absorption and bioavailability.

Some researchers have questioned the safety of ethosomes, the authors wrote, but they said they found no adverse skin reactions in any of the evaluated clinical trials. They also report that post-marketing data has not revealed any other adverse reactions.

Several permeability analyses with microscopy tools showed that the ethosomes can penetrate and efficiently diffuse through the skin carrying hydrophilic and lipophilic drugs. The authors wrote that the versatility of the nanocarriers, their malleability and ability to penetrate the skin effectively, makes them a promising transdermal drug delivery vehicle.

“From various research reports, it can be concluded that ethosomes are the competent and efficient vesicles to provide better drug transport via transdermal route,” they wrote.

Filed Under: Clinical Trials, Featured, Nanoparticles, Preclinical Trials, Research & Development

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS